DB:1VT

Stock Analysis Report

Executive Summary

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Viking Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1VT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.5%

1VT

-8.1%

DE Biotechs

-6.8%

DE Market


1 Year Return

-21.5%

1VT

2.8%

DE Biotechs

6.5%

DE Market

Return vs Industry: 1VT underperformed the German Biotechs industry which returned 2.8% over the past year.

Return vs Market: 1VT underperformed the German Market which returned 6.5% over the past year.


Shareholder returns

1VTIndustryMarket
7 Day-8.5%-8.1%-6.8%
30 Day-1.9%-9.4%-3.7%
90 Day-13.3%-4.5%-3.6%
1 Year-21.5%-21.5%3.0%2.8%9.8%6.5%
3 Year300.6%300.6%31.3%29.9%6.8%-2.6%
5 Yearn/a6.9%4.6%12.5%-2.9%

Price Volatility Vs. Market

How volatile is Viking Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Viking Therapeutics undervalued compared to its fair value and its price relative to the market?

1.59x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: 1VT (€5.75) is trading above our estimate of fair value (€2.21)

Significantly Below Fair Value: 1VT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 1VT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 1VT is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1VT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1VT is good value based on its PB Ratio (1.6x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Viking Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

-25.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1VT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1VT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1VT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1VT's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 1VT's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1VT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Viking Therapeutics performed over the past 5 years?

-2.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1VT is currently unprofitable.

Growing Profit Margin: 1VT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1VT is unprofitable, and losses have increased over the past 5 years at a rate of -2.1% per year.

Accelerating Growth: Unable to compare 1VT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1VT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 1VT has a negative Return on Equity (-8.31%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Viking Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 1VT's short term assets ($289.3M) exceed its short term liabilities ($6.2M).

Long Term Liabilities: 1VT's short term assets ($289.3M) exceed its long term liabilities ($438.0K).


Debt to Equity History and Analysis

Debt Level: 1VT is debt free.

Reducing Debt: 1VT currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: 1VT has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 1VT's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1VT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 1VT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -35.4% each year


Next Steps

Dividend

What is Viking Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 1VT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1VT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1VT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1VT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1VT's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Brian Lian (53yo)

7.4yrs

Tenure

US$1,403,283

Compensation

Dr. Brian Lian, Ph.D., serves as Director at Apricus Biosciences, Inc. He has been the Chief Executive Officer and President at Viking Therapeutics, Inc. since September 24, 2012. Dr. Lian is the Director  ...


CEO Compensation Analysis

Compensation vs Market: Brian's total compensation ($USD1.40M) is above average for companies of similar size in the German market ($USD806.59K).

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Brian Lian
President7.4yrsUS$1.40m2.36% $10.0m
Michael Morneau
Vice President of Finance & Administration1.8yrsUS$619.56k0.11% $480.1k
Gregory Zante
Senior Vice President of Finance0.5yrsno datano data
Amy Broidrick
Senior Vice President of Corporate Development3.1yrsno datano data
Marianne Mancini
Senior Vice President of Clinical Operations2.1yrsno datano data

2.1yrs

Average Tenure

53yo

Average Age

Experienced Management: 1VT's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Brian Lian
President7.4yrsUS$1.40m2.36% $10.0m
Scott Hecker
Scientific Advisor0yrsno datano data
Matthew Foehr
Director5.8yrsUS$81.82k0.054% $229.9k
J. Singleton
Independent Director5.8yrsUS$105.22k0.013% $55.6k
Stephen Webster
Independent Director5.8yrsUS$106.79k0.011% $46.8k
Charles Rowland
Independent Director2.6yrsUS$104.04k0.042% $175.7k
Alan Cherrington
Scientific Advisor0yrsno datano data
G. Fleming
Scientific Advisor0yrsno datano data
David Bullough
Scientific Advisor0yrsno datano data
Lawson MacArtney
Chairman4.7yrsUS$121.91k0.066% $280.9k

5.8yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 1VT's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52.2%.


Top Shareholders

Company Information

Viking Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Viking Therapeutics, Inc.
  • Ticker: 1VT
  • Exchange: DB
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$460.319m
  • Listing Market Cap: US$423.171m
  • Shares outstanding: 72.26m
  • Website: https://www.vikingtherapeutics.com

Number of Employees


Location

  • Viking Therapeutics, Inc.
  • 12340 El Camino Real
  • Suite 250
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VKTXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 2015
1VTDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2015
0VQALSE (London Stock Exchange)YesCommon StockGBUSDApr 2015

Biography

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. The company’s lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in preclinical stage for X-linked adrenoleukodystrophy. The company was founded in 2012 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/26 22:35
End of Day Share Price2020/02/26 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.